

Phase III placebo-controlled double-blind randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Supportive Care in Cancer

Y. Kosaka, Y. Rai, N. Masuda, T. Takano, T. Saeki, S. Nakamura, R. Shimazaki, Y. Ito, Y. Tokuda, K. Tamura

Corresponding Author: Yoshimasa Kosaka, Kitasato University School of Medicine, Sagamihara, Japan;

E-mail: y-kosaka@med.kitasato-u.ac.jp

Online Resource 2 Summary of non-hematologic adverse events in the first cycle of chemotherapy

Event ^a	All adverse events				Drug-related adverse events			
	Pegfilgrastim		Placebo		Pegfilgrastim		Placebo	
	(n = 173)		(n = 173)		(n = 173)		(n = 173)	
	n	%	n	%	n	%	n	%
Alopecia	153	88.4	152	87.9	0	0	0	0
Malaise	87	50.3	76	43.9	22	12.7	16	9.2
Arthralgia	76	43.9	61	35.3	43	24.9	22	12.7
Blood lactate dehydrogenase increased	62	35.8	4	2.3	48	27.7	3	1.7
Constipation	60	34.7	61	35.3	5	2.9	7	4.0
Dysgeusia	57	32.9	54	31.2	4	2.3	4	2.3
Myalgia	54	31.2	44	25.4	21	12.1	14	8.1
Diarrhea	45	26.0	43	24.9	6	3.5	7	4.0
Stomatitis	43	24.9	59	34.1	2	1.2	7	4.0
Decreased appetite	40	23.1	30	17.3	4	2.3	2	1.2
Nausea	36	20.8	40	23.1	5	2.9	4	2.3
Pyrexia	36	20.8	13	7.5	21	12.1	3	1.7
Back pain	33	19.1	26	15.0	25	14.5	13	7.5
Headache	25	14.5	23	13.3	13	7.5	7	4.0
Rash	25	14.5	21	12.1	7	4.0	8	4.6
Eczema	19	11.0	12	6.9	6	3.5	2	1.2

^aAdverse events are listed using terminology from the Japanese version of the Medical Dictionary for Regulatory Activities (version 15.0).